



KRAKOWSKIE
SYMPOZJUM HTA

20 - 21.06.2023

CERTARA^o | EVIDENCE & ACCESS

Program

ZŁOTY SPONSOR

abbvie

janssen 

PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

KRAKOWSKIE SYMPOZJUM HTA

PROGRAM

20 - 21.06.2023

CERTARA[®] | EVIDENCE & ACCESS

Day I

Day I	20.06.2023	09:45 –18:00
Jacek Walczak VP Market Access CEE Certara	Introduction	15 min.
Session I (10:00 – 12:30) Reimbursement in Poland - improvements or stagnation? Moderator: prof. Maciej Niewada / prof. Marcin Czech		
Mateusz Oczkowski, Representant of the Ministry of Health	The reimbursement process in Poland – perspective of the Ministry of Health	20 min.
Dr Jacek Siwiec Representant of the AHTAPol	Drug technologies with high clinical value and a high level of innovation - in the context of the reimbursement process	20 min.
prof. Marcin Czech ISPOR Poland (PTFE)	HTA evolution in PL and EU context	20 min.
prof. Piotr Szymański European Society of Cardiology Board	AOTMIT Transparency Council – what should be changed in the process	15 min.
Jakub Adamski Director, Ombudsman for Patients' Rights	Ombudsman for Patients' Rights perspective	15 min.
DISCUSSION 11:30-12:30 (Speakers and invited persons)		
Coffee break		30 min.
Session II (13:00-14:00) Joint Clinical Assessment (JCA) – Discussion Moderator: Krzysztof Łanda		
Elvira Müller PhD , Certara EvA	EU joint HTA – process and implementation	Discussion panel
Tanja Novakovic ZEM Solutions	Valuing health impact in Slovenia, Croatia and Serbia	
Krzysztof Łanda MD, BCC	Ex – MoH perspective	
Ewa Warmińska-Friberg Director in AHTAPol (TBC)	JCA – perspective of AHTAPol	
Lunch		60 min.

ZŁOTY SPONSOR

abbvie

janssen

PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

Day I

Day I	20.06.2023	15:00-18:00
<p>Session III (15:00-16:30)</p> <p>RWD and open data in Poland and CEE region - where we are?</p> <p>Moderator: Kinga Pacocha Certara INAR</p>		
<p>Artak Khachatryan PhD, MD, Senior Director, Pharmacoepidemiology in Certara</p>	RWD – European and global perspectives	15 min.
<p>Dinidh O'Brien Head of International & Public Relations Data Lake</p>	Securing ethical access to medical data through medical data donation	15 min.
<p>Gabriella Merth, MediConcept</p>	RWD in Hungary – local perspective	15 min.
<p>DISCUSSION 15:45-16:30 (Speakers and invited persons)</p>		
<p>Session IV (16:30-18:00)</p> <p>AI in Evidence Synthesis and Medicine – where we are?</p> <p>Moderator: Jacek Walczak, Certara</p>		
<p>Dr Juan Manuel Fernandez Luna Department of Computer Science and Artificial Intelligence University of Granada</p>	AI - Support algorithms in diagnosis, treatment, and drug development – own experience	15 min.
<p>Izabela Pieniżek Director of the Centre of Excellence Certara INAR</p>	AI in Evidence synthesis – Increase work productivity with AI – <i>real-life experience based on Selextra internal tool</i>	15 min.
<p>Ligia Kornowska Managing Director of the Polish Hospital Federation</p>	AI Coalition in Healthcare	15 min.
<p>Prof. Dr. Sergey Morozov, Chief Innovation Officer in Osimis</p>	Evidence-based AI and its ROI for medical imaging: current status and challenges	15 min.
<p>DISCUSSION 17:30-18:00 (Speakers and invited persons)</p>		

DINNER WITH EXPERTS: 19:00

ZŁOTY SPONSOR

abbvie

janssen 

PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

Day II

Day II	21.06.2023	09:00 – 12:30
<u>Session I (09:00-11:00)</u>		
The CEE and CA region: early access program – a new opportunity		
Moderator: Malwina Hołownia-Voloskova, Certara INAR		
Malwina Hołownia-Voloskova PhD, Ass. Director, Certara INAR	Central Eastern Europe and Central Asia regions – early access to drugs as new opportunity	15 min.
Ajda Lapornik Regional Market Access Lead CEE & SEE in MSD	Pharma perspective on CEE market	15 min.
Anastasiia Havrysh, Market Access Manager at Eirhub	Early Access program in Ukraine and Baltic countries	15 min.
Rok Hren, PhD, MSc IHP (HE), Syreon Research Institute, Budapest; Faculty of Mathematics and Physics, University of Ljubljana, Slovenia	Implementation of Managed Entry Agreements in Central & Eastern Europe	15 min.
Sergey Soshnikov PhD Associate Professor, Bukhara State Medical Institute	Rationale for early access of drugs in Central Asia countries: An In-Depth Analysis of the Indirect Economic Cost of HIV/AIDS in Uzbekistan	15 min.
Prof. John Yfantopoulos University of Athens	Early Access to medicine in Greece	15 min.
DISCUSSION 10:30-11:00 (Speakers and invited persons)		
Coffee break		15 min.
<u>Session II (11:15-12:30)</u>		
Oncological & orphan drugs – medical and patients' perspectives		
Moderator: Joanna Jarosz		
Prof. Grzegorz Basak Medical University of Warsaw	CAR-T – real-life experience in Poland	15 min.
Prof. Zbigniew Żuber Szpital Dziecięcy Św. Ludwika w Krakowie	Rare diseases – clinicians' perspective	15 min.
Polish MPS Society representative	Patients' perspective	15 min.
Q&A		

ZŁOTY SPONSOR

abbvie

janssen 

PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

KRAKOWSKIE SYMPOZJUM HTA

20 - 21.06.2023

CERTARA^o | EVIDENCE & ACCESS

PREVIOUS EDITIONS



On YouTube



VII edition

VI edition

21

PRELEGENTS

147

PARTICIPANTS